WO2007110704A3 - Macrolide compositions as therapeutic agent - Google Patents

Macrolide compositions as therapeutic agent Download PDF

Info

Publication number
WO2007110704A3
WO2007110704A3 PCT/IB2006/004213 IB2006004213W WO2007110704A3 WO 2007110704 A3 WO2007110704 A3 WO 2007110704A3 IB 2006004213 W IB2006004213 W IB 2006004213W WO 2007110704 A3 WO2007110704 A3 WO 2007110704A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
cancer
macrolide compositions
related disorders
treatment
Prior art date
Application number
PCT/IB2006/004213
Other languages
French (fr)
Other versions
WO2007110704A2 (en
Inventor
Bernard Mach
Peter Traxler
Krzysztof Masternak
Horst Flotow
Guo Xuming
Mui Mui Sim
Chee Wee Phoon
Original Assignee
Novimmune Sa
Merlion Pharmaceuticals Pte Lt
Bernard Mach
Peter Traxler
Krzysztof Masternak
Horst Flotow
Guo Xuming
Mui Mui Sim
Chee Wee Phoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Merlion Pharmaceuticals Pte Lt, Bernard Mach, Peter Traxler, Krzysztof Masternak, Horst Flotow, Guo Xuming, Mui Mui Sim, Chee Wee Phoon filed Critical Novimmune Sa
Publication of WO2007110704A2 publication Critical patent/WO2007110704A2/en
Publication of WO2007110704A3 publication Critical patent/WO2007110704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention provides macrolide compounds, and pharmaceutically acceptable salts thereof, that inhibit MHC class II expression and that can be used as immunosuppressive agents in the treatment prior to, during and/or after organ or tissue transplantation, as well as in the treatment of immune-related disorders and/or cancer and cancer-related disorders.
PCT/IB2006/004213 2005-09-28 2006-09-27 Macrolide compositions as therapeutic agent WO2007110704A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72151305P 2005-09-28 2005-09-28
US60/721,513 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007110704A2 WO2007110704A2 (en) 2007-10-04
WO2007110704A3 true WO2007110704A3 (en) 2008-02-14

Family

ID=38541484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/004213 WO2007110704A2 (en) 2005-09-28 2006-09-27 Macrolide compositions as therapeutic agent

Country Status (1)

Country Link
WO (1) WO2007110704A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7334181B2 (en) 2018-04-12 2023-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pladienolide derivatives as spliceosome-targeting agents for cancer therapy

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821539D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Therapeutic compounds and their use
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380579A1 (en) * 2001-02-01 2004-01-14 Mercian Corporation Novel physiologically active substances
WO2006000923A2 (en) * 2004-06-03 2006-01-05 Novimmune Sa Macrolide compositions as therapeutic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380579A1 (en) * 2001-02-01 2004-01-14 Mercian Corporation Novel physiologically active substances
WO2006000923A2 (en) * 2004-06-03 2006-01-05 Novimmune Sa Macrolide compositions as therapeutic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEKI-ASANO M ET AL: "ISOLATION AND CHARACTERIZATION OF A NEW 12-MEMBERED MACROLIDE FD-895", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 47, no. 12, December 1994 (1994-12-01), pages 1395 - 1401, XP002951021, ISSN: 0021-8820 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7334181B2 (en) 2018-04-12 2023-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pladienolide derivatives as spliceosome-targeting agents for cancer therapy

Also Published As

Publication number Publication date
WO2007110704A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
IL260127B (en) Mek inhibitors and methods of their use
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007011962A3 (en) Treatment of cancer
EP2056818A4 (en) Compositions and methods for neuroprotection
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2004110390A3 (en) Anti-cd74 immunoconjugates and methods
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2012027065A3 (en) Combination therapy for treatment of disease
EP2476461A3 (en) Formulations For Cancer Treatment
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2006086693A3 (en) Medical devices
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2005060960A3 (en) Use of histamine to treat bone disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06849544

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 06.08.08.

122 Ep: pct application non-entry in european phase

Ref document number: 06849544

Country of ref document: EP

Kind code of ref document: A2